Novel Potent TIM-3 Inhibitors were discovered in ChemDiv’s collection.
The ChemDiv’s proprietary library of chemically diverse small molecule compounds was demonstrated to be a source of selective inhibitors targeting specific check points was found out in a recent preclinical study. In a collaborative effort, researchers from the Molecular Imaging Innovations Institute at Weill Cornell Medicine and Freie Universitaet Berlin used a selective set of the ChemDiv’s small molecule library to study a novel class of drugs engaging with the T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Published by Abdel-Rahman et al. in the Journal of Medicinal Chemistry,1 the study highlights the library’s compounds for their exceptional selectivity, affinity, and inhibitory action against TIM-3.
TIM-3 has emerged as a significant therapeutic target for chemotherapeutics against Acute Myeloid Leukemia (AML). The encouraging outcomes of the study confirm that our in-depth research, focusing on the molecular interactions of drug compounds with specific target moieties, unveils their potential to disrupt crucial pathways in the AML cells. ChemDiv's expertise in medicinal chemistry and drug design was instrumental in this discovery, showcasing our ability to pioneer novel treatments in the highly complex field of cancer therapies. Meanwhile, ChemDiv’s team of expert scientists continues to make efforts to expand our compound library, known for its remarkable chemical diversity and the highest quality of medicinal chemistry.
About ChemDiv
ChemDiv is committed to partnering in the discovery and development of groundbreaking therapies, utilizing its unique chem-bio platforms. These include molecular glues, stabilizers, and degraders; covalent and non-covalent binders; and bifunctional molecules for synergistic effects and synthetic lethality. Over the past 30 years, ChemDiv has successfully completed hundreds of lead, candidate, and new drug programs in collaboration with pharma, biotech, and academic partners globally, targeting cancer, neurological, infectious, cardiometabolic, and immune diseases. Learn more at www.chemdiv.com
1 Abdel-Rahman SA, Talagayev V, Pach S, Wolber G, Gabr MT. Discovery of Small-Molecule TIM-3 Inhibitors for Acute Myeloid Leukemia Using Pharmacophore-Based Virtual Screening. J Med Chem. 2023 Aug 24;66(16):11464-11475. doi: 10.1021/acs.jmedchem.3c00960.
